What amount of fatigue is associated with seizures and antiepileptic drugs?

Fatigue from Antiepileptic Medications

Fatigue is a common adverse effect of antiepileptic drugs (AEDs), occurring in approximately 34-52% of patients with epilepsy, though the relationship between specific medications and fatigue severity is complex and often confounded by seizure frequency, depression, and sleep disturbance.

Medication-Specific Fatigue Profiles

Based on the American Academy of Neurology guidelines and meta-analyses, the following AEDs are associated with fatigue 1:

High Fatigue Risk:

• Gabapentin: Somnolence and fatigue are among the most frequent adverse events (discontinuation rate 3-11.5%) 1
• Pregabalin: Fatigue occurs with a risk difference of 0.04-0.08 compared to placebo, along with somnolence (0.11) 2
• Topiramate: Fatigue risk difference of 0.06 (0.01-0.12) compared to placebo, with dose-dependent effects 2

Moderate Fatigue Risk:

• Lamotrigine: Primarily causes dizziness and ataxia; fatigue less prominent 1
• Levetiracetam: Somnolence risk difference 0.06 (0.01-0.11) 2
• Oxcarbazepine: Fatigue reported among the five most common adverse events alongside dizziness and sedation 1

Lower Fatigue Risk:

• Zonisamide: Somnolence risk difference 0.06 (0.02-0.11) 2

Critical Dose-Response Relationships

The dose of medication matters significantly more than the type of medication alone 3:

• Carbamazepine doses positively correlate with fatigue severity (p=0.042) 3
• Levetiracetam doses positively correlate with fatigue severity (p=0.023) 3
• Valproic acid and lamotrigine doses show no significant correlation with fatigue 3

The Confounding Factor Problem

A crucial clinical pitfall: Fatigue in epilepsy patients cannot be attributed solely to medications 4, 5. The most recent high-quality evidence (2025) demonstrates:

Primary Drivers of Fatigue (in order of importance):

1. Anxiety symptoms (GAD-7 correlation: r=0.510, p<0.001) 4
2. Overall adverse medication effects (LAEP correlation: r=0.565, p<0.001) 4
3. Depression symptoms (NDDI-E correlation: r=0.453, p<0.001) 4
4. Seizure frequency (higher frequency = more fatigue, p=0.031) 3, 6
5. Perceived treatment efficacy (inverse correlation: r=-0.277, p<0.001) 4

What Does NOT Predict Fatigue:

• Number of AEDs used 3, 4
• Specific type of AED (when controlling for other factors) 3, 4
• Duration of AED use 4
• Recent changes in medication regimen 4

Clinical Algorithm for Managing Fatigue

When a patient reports fatigue:

1. Screen for depression and anxiety first - These mediate 18.5-23.7% of the fatigue effect and are treatable 5

2. Assess seizure control - Uncontrolled seizures (>1/month) are independently associated with higher fatigue scores (FSS 6.28 vs 2.30 in controlled patients) 6, 7

3. Evaluate medication adherence - Missing even one dose in the past month correlates with higher fatigue 4

4. Consider dose reduction rather than medication switching - For carbamazepine and levetiracetam specifically, lower doses may reduce fatigue without changing the drug 3

5. Address sleep quality - Poor sleep quality increases ASM resistance risk (HR 2.193) and is partly mediated by depression 5

Key Clinical Caveats

• Baseline fatigue predicts medication resistance: Patients with fatigue at diagnosis have nearly 2× higher risk of developing drug-resistant epilepsy (HR 1.98, p=0.024) 5

• Post-ictal vs inter-ictal fatigue: Fatigue scores are higher post-ictally (79/160) than inter-ictally (62/160), so timing of assessment matters 8

• Gender differences: Female patients report significantly higher fatigue scores (p=0.038) 4

• The "adverse effect profile" matters more than individual drugs: Total medication burden (measured by LAEP) is the strongest predictor in regression models 4

Bottom line: When fatigue is reported, aggressively treat depression and anxiety, optimize seizure control, and consider dose reduction of carbamazepine or levetiracetam before switching medications entirely.